Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib

Open access
Draganova, Dafina, Kerger, Joseph, Caspers, Laure, Willermain, François · 2015 · Journal of Ophthalmic Inflammation and Infection

Abstract

BACKGROUND: We report a case of severe bilateral panuveitis during melanoma therapy with a combination of Dabrafenib, a B-raf (BRAF) inhibitor, and Trametinib, a mitogen/extracellular signal-regulated kinase (MEK) inhibitor. Both of these drugs are effectors in the mitogen-activated protein kinase (MAPK) pathway, which plays an important role in the physiopathology of melanoma. Dabrafenib and Trametinib have shown improved survival of patients with metastatic melanoma but they have also been associated with the development of uveitis. FINDINGS: Our patient was a 55-year-old woman with metastatic melanoma who presented with sudden onset of bilateral painless visual loss. She had been treated with Dabrafenib and Trametinib. Trametinib was discontinued at the onset of symptoms but there was no improvement. Ophthalmological examination revealed severe bilateral non-granulomatous panuveitis, with choroidal thickening, chorio-retinal folds, and multiple serous retinal detachments (SRDs). Topical corticosteroid treatment was initiated, and Dabrafenib was discontinued. A good response was obtained with a recovery of visual acuity of 20/25 on both eyes and an almost complete resolution of the SRDs. CONCLUSIONS: This case highly suggests that MAPK pathway inhibition can lead to severe uveitis. Dabrafenib and Trametinib could have both played a role in inducing the disease. Further studies are needed to evaluate the possible role of the combination of these drugs in inducing uveitis and SRD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12348-015-0049-9

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Color fundus photographs. a, b Upper panel: at presentation, fundus details are masked by anterior fibrin and vitreous haze resulting from severe inflammation, but optic disk hyperhemia can be detected on the left side. The superonasal round yellow area on the left side is an artifact. c, d Lower panel: 1 month after drug arrest, resolution of the inflammation allows normal fundus visualization including normal optic disks
Fig. 1 Color fundus photographs. a, b Upper panel: at presentation, fundus details are masked by anterior fibrin and vitreous haze resulting from severe inflammation, but optic disk hyperhemia can be detected on the left side. The superonasal round yellow area on the left side is an artifact. c, d Lower panel: 1 month after drug arrest, resolution of the inflammation allows normal fundus visualization including normal optic disksCC BY · PubMed Central
Fig. 2 HR-OCT. a, b Upper panel: at presentation: multiple serous retinal detachments, loss of normal choroidal vascular architecture, and chorio-retinal folds are observed. c, d Lower panel: 1 month after drug arrest, there is an almost complete resolution of the serous retinal detachments and of the chorio-retinal folds
Fig. 2 HR-OCT. a, b Upper panel: at presentation: multiple serous retinal detachments, loss of normal choroidal vascular architecture, and chorio-retinal folds are observed. c, d Lower panel: 1 month after drug arrest, there is an almost complete resolution of the serous retinal detachments and of the chorio-retinal foldsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 63

Metadata

Authors
Draganova, D., Kerger, J., Caspers, L., & Willermain, F.
Affiliations
  • Centre Hospitalier Universitaire de Saint-Pierre (BE)
  • Institut Jules Bordet (BE)
Corresponding author
Draganova, Dafina
Venue
Journal of Ophthalmic Inflammation and Infection
Published
2015-06-09
Volume
5
Issue
1
Pages
17-17
ISSN
1869-5760 (ISSN-L)
OpenAlex
W1828732496
Cited by
62
References
10
Citations by year
2026: 2 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 12 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 6 · 2016: 5 · 2015: 1
FWCI
5.77
Type
journal article
Language
en
Open access
Locations
  • Journal of Ophthalmic Inflammation and Infection (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
Keywords
panuveitis, uveitis, melanoma, dabrafenib, trametinib, BRAF inhibitors, MEK inhibitors, MAPK inhibition, drug-induced uveitis, serous retinal detachment, choroidal thickening, metastatic melanoma, topical corticosteroids, vision loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. https://app.cochat.ai/papers/10.1186/s12348-015-0049-9
The paper
Draganova, D., Kerger, J., Caspers, L., & Willermain, F. (2015). Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. Journal of Ophthalmic Inflammation and Infection. https://doi.org/10.1186/s12348-015-0049-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.